Autoinjectors Market

The global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of  USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%. The key factors driving the growth of the global autoinjectors market are the growing launch of technologically advanced autoinjector devices, rise in regulatory approvals for finish formulations in autoinjector format, and increased adoption of home-based therapies by patients.

The market for autoinjectors is consolidated, with key players strategizing to capture the majority of the market. Prominent players in the autoinjectors market are SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc. (US), Owen Mumford Ltd. (UK), Gerresheimer AG (Germany) and among others. Some of the major market players for finished formulations covered in this chapter include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Jonhson & Jonhson Services Inc. (US), Sanofi (France), GSK plc (UK).

To know about the assumptions considered for the study download the pdf brochure

SHL Medical AG is the leading market player in the autoinjectors market. The company offers a wide range of autoinjector products for low to high-volume formulations. The has a strong emphasis on the launch of technologically advanced autoinjector devices in the market, contributing towards the company’s dominant position in the market. Furthermore, the company is planning to ramp up its production capacity in order to meet the demand for the autoinjectors in coming years.

Ypsomed AG is one of the dominant players in the global autoinjector market. Ypsomed offers an extensive product portfolio of self-injection device systems and infusion systems. The company's strong focus on geographic presence and launch of patient-centric autoinjector products influence to dominant market share. Ypsomed generally focuses on employing inorganic and organic growth strategies to maintain its strong position in the market. The company has alliances and supply agreements with a few of the leading drug manufacturers globally. For instance, in September 2023, Ypsomed and Novo Nordisk entered into a long-term supply agreement for an massive quantity of autoinjectors.

Becton, Dickinson and Company (BD) is one of the prominent players in the autoinjectors market. BD offers diversified drug delivery systems. The company's dominant position in the market is due to its strong brand presence, innovative product offerings, and strategies adopted by the company, such as collaborations, partnerships, and agreements. Additionally, a strong focus on expanding the company's presence in emerging markets is further likely to strengthen BD's market position in the autoinjectors market. Furthermore, BD leverages its extensive global distribution network worldwide. This includes partnerships with local distributors and direct sales channels.

Related Reports:

Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]